Table 1. . Examples of post isolation modifications to exosomes for nanomedicine purposes.
Exosome type | Modification | Strategy | Purpose | Ref. |
---|---|---|---|---|
Human embryonic kidney 293T |
Engineered structure modification |
Attach fluorescent Alex Fluor® 680-Streptavidin to luciferase-biotin surface fusion protein |
Enable dual bioluminescent and fluorescent imaging |
[16] |
Mouse 4T1 breast cancer |
Natural structure modification |
Conjugate surface protein amine groups to Azide-Fluor 545 using ‘click chemistry’ |
Enable fluorescent imaging of exosomes |
[17] |
Mouse MSC |
Natural structure repurposing |
Transfer bioactive PD-L1 to autoreactive T cells |
Inhibit autoreactive T cells in an EAE mouse model |
[18] |
Mouse N2a neuroblastoma |
Natural structure repurposing |
Transfer aβ aggregates on glycosaminoglycans to brain microglial cells for removal |
Evaluate a new therapeutic approach for Alzheimer's disease using a mouse model |
[19] |
Mouse EL-4 T-cell lymphoma |
Passive loading of hydrophobic cargo |
Load anti-inflammatory curcumin into exosome membranes |
Increase curcumin stability and efficacy in a septic shock model |
[20] |
Mouse EL-4 T-cell lymphoma |
Passive loading of hydrophobic cargo |
Load anti-inflammatory curcumin or JSI-124 into exosome membranes |
Test intranasal therapy for inflammatory brain conditions in mouse models |
[21] |
Mouse DC |
Electroporation of hydrophilic cargo |
Load siRNA to BACE1 into exosomes expressing RVG-Lamp2b which binds to ACh receptors |
Deliver siRNA to BACE1, an Alzheimer's disease target, across the blood–brain barrier in a mouse model |
[22] |
Mouse DC |
Electroporation of hydrophilic cargo |
Load siRNA to α-synuclein into exosomes expressing RVG-Lamp2b which binds ACh receptors |
Deliver siRNA to α-synuclein, a Parkinson's disease target, across the blood–brain barrier in a mouse model |
[23] |
Human plasma exosomes |
Electroporation of hydrophilic cargo |
Load siRNA to MAPK-1 into exosomes |
Suppress MAPK-1 in monocytes and lymphocytes |
[24] |
Mouse M12.4 B lymphocyte |
Electroporation of hydrophilic cargo |
Load miRNA-155 inhibitor into exosomes |
Suppress LPS-induced TNF-α production in macrophages |
[25] |
Human MDA-MB231, HUVEC, hMSC, hESC |
Electroporation of hydrophilic cargo |
Load porphyrin model drugs into different types of exosomes |
Test encapsulation efficiency of porphyrins based on hydrophobicity and loading method |
[7] |
Mouse immature DC |
Electroporation of hydrophilic cargo |
Load doxorubicin into Lamp2b-αV-integrin-specific iRGD peptide expressing exosomes |
Target and treat αV-integrin expressing breast tumors in mice |
[26] |
Human MDA-MB231 breast cancer, HCT-116 colon cancer |
Electroporation of hydrophilic cargo |
Load doxorubicin into exosomes |
Improve doxorubicin efficacy and reduce cardiotoxicity in a breast cancer model |
[27] |
Mouse aortic primary endothelial cell |
Electroporation of hydrophilic cargo |
Load siRNA to luciferase into exosomes |
Determine autocrine uptake efficiency of endothelial exosomes by endothelial cells |
[28] |
Mouse B16-F10 melanoma |
Electroporation of hydrophilic cargo |
Load 5 nm superparamagnetic iron oxide nanoparticles (SPION5) into exosomes using trehalose pulse media |
Develop a trehalose pulse media to maximize exosome colloidal stability during cargo loading via EP |
[11] |
Mouse B16-F10 melanoma | Electroporation of hydrophilic cargo | Load theranostic SPION5 cargo into exosomes | Track exosome homing to lymph nodes in mice using MRI | [29] |
DC: Dendritic cell; EAE: Experimental autoimmune encephalitis; LPS: Lipopolysaccharide; MSC: Mesenchymal stem cell.